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Abstract
The Wilson disease (WD) protein (ATP7B) is a copper-transporting P-type ATPase that is responsible for the efflux of hepatic copper into
the bile, a process that is essential for copper homeostasis in mammals. Compared with other mammals, sheep have a variant copper
phenotype and do not efficiently excrete copper via the bile, often resulting in excessive copper accumulation in the liver. To investigate the
function of sheep ATP7B and its potential role in the copper-accumulation phenotype, cDNAs encoding the two forms of ovine ATP7B were
transfected into immortalised fibroblast cell lines derived from a Menkes disease patient and a normal control. Both forms of ATP7B were
able to correct the copper-retention phenotype of the Menkes cell line, demonstrating each to be functional copper-transporting molecules and
suggesting that the accumulation of copper in the sheep liver is not due to a defect in the copper transport function of either form of sATP7B.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Copper homeostasis is important because copper is an
essential trace element but is toxic in excess, so organisms
require mechanisms to maintain intracellular copper at the
required level [1]. In humans and other mammals, the liver
is the major organ involved in the regulation of overall
copper status, with excess copper being excreted from the
body in the bile [2]. The importance of the biliary excretion
pathway is illustrated by the human copper toxicosis dis-
order Wilson disease (WD). Patients with this disease
cannot excrete copper into the bile, resulting in hepatic
copper accumulation and if untreated, fatal copper toxicosis.
A second feature of most, but not all WD patients, is very
low serum ceruloplasmin levels [3]. The gene that is
defective in WD patients encodes a copper-transporting P-
type ATPase (ATP7B) [4–6]. ATP7B has two functional
roles in copper homeostasis in the liver. The first is the
transport of copper into the lumen of the Golgi apparatus for
incorporation into secreted copper-dependent enzymes, pri-
marily ceruloplasmin [7]. The second role of ATP7B is the
excretion of excess copper into the bile. This involves
copper-induced trafficking of ATP7B from the trans-Golgi
network (TGN) or late endosomic vesicles, to vesicles and
the apical biliary canalicular membrane when copper is
present in excess [8–10]. The dual roles of ATP7B may
explain the heterogeneity in clinical features of patients
presenting with WD, with different ATP7B alleles affecting
either copper transport or intracellular location/trafficking of
ATP7B [8]. Recently, a cell culture system was utilised to
distinguish ATP7B variants in which copper transport was
disrupted from those in which intracellular trafficking was
impaired [11].
Sheep have a variant copper phenotype when compared
with other mammals. The species is prone to copper
deficiency due to the formation of copper-chelating thio-
molybdates in the rumen [12]. However, sheep are prone to
copper toxicosis due to a reduced capacity to excrete copper
in the bile. Unlike most mammals, the rate of biliary copper
excretion is not responsive to copper intake [13]. Analogous
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to WD patients, the intake of moderate dietary levels of
copper can result in elevated hepatic copper concentrations,
liver failure and death [14]. Unlike most WD patients, the
level of copper and holoceruloplasmin in sheep plasma is
similar to the normal human range [15]. We are investigat-
ing the molecular basis of the sheep copper phenotype. In
previous studies, we cloned the sheep ATP7B (sATP7B)
cDNA, but did not find any obvious abnormality of struc-
ture or expression that would suggest that sheep have a
defect in ATP7B. However, we identified a novel form of
the ATP7B cDNA which had an alternative N-terminal
region, generated by alternate splicing [16]. The form
corresponding to published ATP7B orthologues (normal
sATP7B) encodes an 18-amino-acid N-terminal sequence,
which is replaced by a novel 79-amino-acid sequence in the
alternate sATP7B protein. Both forms of sATP7B localise to
the TGN and undergo copper-induced trafficking to a
vesicular compartment when expressed in CHO cells [17].
In this study, we examined the copper-translocating
activity of each form of sATP7B to determine if the sheep
copper phenotype might be related to alterations in this
activity in either form of sATP7B. The copper transport
function of both forms of sATP7B was examined in vitro by
the generation of fibroblast cell lines from a Menkes disease
patient and a normal control, which expressed cDNA-
derived sATP7B. Although exogenously expressed ATP7B
does not undergo copper-induced trafficking in this cell line,
the copper transport function of introduced ATPases can be
accurately assessed by measuring efflux of radiolabeled
copper from the cell. Our results indicate that both forms
of sATP7B correct the copper accumulation defect of
Menkes patient fibroblasts and therefore are functional
copper-transport proteins.
2. Materials and methods
2.1. Cell culture, constructs and antibodies
The generation and characterisation of immortalised
fibroblasts derived from a Menkes disease patient (Me32a-
T22/2L) and control cell line (GM847) has been previously
described. The Me32a MNK gene has a 4-base-pair (bp)
deletion within exon 6, resulting in a prematurely terminated
protein between metal binding sites 5 and 6, and complete
loss of the protein as determined by Western blot utilising a
polyclonal antibody directed against all six metal binding
sites [18]. Cells were maintained at 37 jC in basal medium
(approximately 1 AM copper), which consisted of Eagle’s
basal medium (BME) (Trace BioSciences) supplemented
with 2 mM L-glutamine, 0.2 mM proline, 1.2 mM NaHCO3,
20 mM HEPES and 10% foetal calf serum (Commonwealth
Serum Laboratories). The generation of the constructs
pNORM and pALT, encoding the normal and alternate
forms of sheep ATP7B cloned into a low-copy number
mammalian expression vector was reported previously, as
was the production, purification and characterisation of
antibodies specific for each form of sheep ATP7B [17].
2.2. Cell transfection and expression analysis
The transfection of cells was performed essentially as
described previously [17]. Briefly, stable transfection of
cultured cells was performed with 20 Ag of linear plasmid
DNA and Superfect reagent (Qiagen) according to the
manufacturer’s protocols. Following 3 weeks of G418
selection (Gibco, 400 Ag/ml), resistant colonies were
detached, expanded and maintained as a mixed population
of G418-resistant cells. Approximately 60–80% of the
G418-resistant population expressed sATP7B, as deter-
mined by immunofluorescence analysis (see below). The
transfected cell populations were routinely cultured in the
presence of G418 (200 Ag/ml) to maintain selective pres-
sure for expression of the ATP7B transgene. The generation
and characterisation of Me32a-T22/2L cells expressing
mouse Atp7b was reported previously [18]. Total RNA
was prepared from cells and the expression of each ATP7B
transcript was analysed utilising a ribonuclease protection
assay (RPA) as described previously [16]. Total protein
extracts were prepared from approximately 5 106 cells as
previously described [19]. The protein concentration was
estimated by absorbance at 280 nm and approximately 15
Ag of each sample was separated by SDS-PAGE on 7.5%
gels (Bio-Rad) under reducing conditions and transferred to
nitrocellulose membranes (Millipore). Immunoblot analysis
was carried out using the BM Chemiluminescence Kit
(Boehringer Mannheim) according to the manufacturer’s
protocols. Filters were incubated overnight at 4 jC in
blocking buffer and incubated for 1–5 h with the appro-
priate affinity-purified primary antibody at room temper-
ature. After four washes in blocking solution, filters were
incubated for 1 h with horseradish peroxidase-conjugated
sheep anti-rabbit IgG (Amrad Pharmacia Biotech) and
immunoreactive proteins were visualised by chemilumi-
nescence.
2.3. Immunofluorescence microscopy
Immunofluorescence analysis of cells was carried out
essentially as described previously [20]. Where appropriate,
copper (as CuCl2) was added to the growth medium. In
general, cells were grown to 60% confluence on glass cover
slips, fixed with 4% paraformaldehyde in PBS for 5 min,
permeabilised with 0.1% Triton X-100 in PBS for 5 min at
room temperature and placed in blocking solution (1%
BSA/1% gelatin in PBS) overnight at 4 jC. Primary anti-
bodies consisted of affinity-purified anti-normal and anti-
alternate sheep ATP7B antibodies (1:100 or 1:50) and an
affinity-purified anti-mouse Atp7b (1:50) antibody des-
cribed previously [18]. The secondary antibody was
affinity-purified FITC-conjugated sheep anti-rabbit IgG
(Amrad Pharmacia Biotech, 1:400). The cover slips were
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mounted onto glass slides using 2.6% DABCO (1,4-diaza-
bicyclo-(2.2.2) octane, Sigma) in 100% glycerol and ana-
lysed using a Zeiss axioskop fluorescence microscope with
a CCD camera (Photometrics) and V for Windows software
(Digital Optics).
2.4. 64Cu accumulation and retention studies
Copper accumulation studies were performed as
described [18]. Briefly, cells were cultured in basal medium
and transferred to BME supplemented with 2% foetal calf
serum and trace amounts of 64Cu (approximately 0.5 AM as
CuCl2; Australian Radioisotopes). For accumulation studies,
cells were incubated for 24 h at 37 jC, washed twice in cold
BME, and harvested by homogenisation in 0.1% SDS. For
retention experiments, cells were treated as above but with
an 8-h incubation in BME containing 2% foetal calf serum
but lacking 64Cu. The cells then were washed twice with
cold BME and harvested in 0.1% SDS. The amount of 64Cu
in the cell lysates was measured using an LKB-Wallac
Ultragamma counter and the protein content of the extracts
was determined by protein assay [21].
3. Results
3.1. Transfection and expression analysis of sheep ATP7B in
Menkes patient and control fibroblasts
Expression constructs encoding the normal (pNORM)
and alternate (pALT) sATP7B cDNAs were transfected into
immortalised fibroblast cell lines, one control, GM847 and
one derived from a Menkes disease patient, Me32a-T22/2L.
To confirm expression of the sheep ATP7B cDNA, total
RNA was extracted from 5 106 cells and 3 Ag was
analysed by a RPA. A protected fragment of the expected
size (approximately 180 bp) was observed in Me32a-T22/
2L and GM847 cells transfected with pNORM, but not in
the corresponding untransfected cells or those transfected
with pALT (Fig. 1). Similarly, a protected fragment of
expected size (approximately 340 bp) was detected in cells
transfected with pALT but not in untransfected cells or
pNORM-transfected cells (Fig. 1).
Western blot analysis was carried out to confirm the
expression of sheep ATP7B and to determine the relative
level of protein expression. Approximately 15 Ag of whole
cell protein extract from the transfected and control cell
lines was analysed. A protein of the expected size (approx-
imately 180 kDa) was detected in the appropriate cell lines
following analysis with either the anti-normal or anti-alter-
nate ATP7B antibody (Fig. 2). There was no evidence of
ATP7B protein in the untransfected cell lines. This result
was expected as these cells do not express detectable levels
of endogenous human ATP7B mRNA [18] and the sheep
ATP7B antibodies do not cross-react with human ATP7B or
human ATP7A (data not shown). The lower molecular
Fig. 1. RPA of sATP7B expression in transfected fibroblast cells. Total RNA
was isolated from transfected cells and 3 Ag was analysed by RPA as
described in the Materials and methods. Lane 1 shows the size of the full-
length, undigested probe and lane 2 the probe treated with ribonuclease.
The RNA samples are: lane 3, untransfected Me32a Menkes patient
fibroblasts; lane 4, untransfected GM847 normal fibroblasts; lane 5, Me32a
transfected with pNORM; lane 6, Me32a transfected with pALT; lane 7,
GM847 transfected with pNORM; lane 8, GM847 transfected with pALT.
The approximately 340 and 180 bp protected fragments correspond to the
alternative and normal sATP7B transcripts, respectively.
Fig. 2. Western blot analysis of sATP7B expressed in fibroblast cells.
Approximately 15 Ag of total protein extract from fibroblast cells was
fractionated by SDS-PAGE (7.5%) and duplicate gels were transferred to
nitrocellulose membranes. Sheep ATP7B was detected with affinity-
purified anti-normal sATP7B (A, 1:100) or anti-alternate sATP7B antibody
(B, 1:50) and enhanced chemiluminescence. The samples are: Me32a,
untransfected Me32a Menkes patient fibroblasts; GM847, untransfected
GM847 normal fibroblasts; Me32a/pNORM, Me32a transfected with
pNORM; Me32a/pALT, Me32a transfected with pALT; GM847/pNORM,
GM847 transfected with pNORM; GM847/pALT, GM847 transfected with
pALT. The position of the approximately 160 kDa sATP7B protein is
indicated.
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weight bands observed with the anti-alternate sATP7B
antibody probably represent non-specific background, since
they also were visible in the untransfected samples follow-
ing an increased exposure time (data not shown).
3.2. Intracellular distribution of sheep ATP7B in Menkes
patient and control fibroblasts
Immunofluorescence analysis was used to confirm
expression and assess the intracellular distribution of each
form of the sheep ATP7B protein in Menkes patient and
control fibroblasts. In basal medium, each form of sheep
ATP7B was similarly localised to the perinuclear region of
transfected Menkes patient cells (Fig. 3A,B). A similar
distribution was observed for each form of sATP7B in the
control cell line (data not shown). This localisation of
sATP7B was similar to that of murine Atp7b when
expressed in the same cell line (Fig. 3C) and was consistent
with previous studies, which demonstrated that sheep,
mouse and human ATP7B is located at the TGN [17,18,22].
3.3. Copper accumulation and retention studies in trans-
fected fibroblasts
Copper transport studies were carried out to determine if
the sheep ATP7B proteins could correct the abnormal
copper accumulation of Menkes patient fibroblasts, as was
reported for mouse and human ATP7B [18,23]. Following a
24-h incubation in media containing approximately 0.5 AM
64Cu, the parental Me32a cell line accumulated approxi-
mately three-fold more copper than the control GM847 cell
line (Table 1). The copper accumulation in Me32a cells
transfected with either form of sheep ATP7B was signifi-
cantly reduced in comparison to the non-transfected Me32a
cells and was comparable to, or lower than the copper
accumulation of the control cell line GM847 (Table 1).
Further, the copper accumulation of normal fibroblasts
(GM847) transfected with either form of sheep ATP7B
Fig. 3. Immunofluorescence microscopy analysis of ATP7B expressed in
fibroblast cells. Transfected Menkes patient fibroblast cells expressing
normal sATP7B (A), alternate sATP7B (B) or mouse Atp7b (C) were grown
in basal media. The cells were fixed with 4% paraformaldehyde and
permeabilised with 0.1% Triton X-100 before staining by indirect
immunofluorescence with affinity-purified antibodies raised against normal
sATP7B (1:100), alternate sATP7B (1:50) and mouse Atp7b (1:50). Primary
antibodies were detected using affinity-purified FITC-conjugated sheep
antibodies to rabbit IgG. Bar: 10 Am ( 60 objective).
Table 1
Copper accumulation and efflux by fibroblasts expressing sATP7B
Cell line 24 h Copper
accumulation
(pmol Cu/Ag protein,
meanF S.D.)
Percentage
copper retention
(meanF S.D.)
Me32a 0.65F 0.04 76F 1.2
GM847 0.25F 0.01 49F 1.7
Me32a–pNORM 0.2F 0.03 36F 1.5
Me32a–pALT 0.006F 0.001 30F 2
GM847–pNORM 0.006F 0.001 34F 3.5
GM847–pALT 0.006F 0.001 32F 1.7
Transfected and untransfected Menkes patient fibroblast (Me32a) and
control fibroblast cells (GM847) were grown in 64Cu-containing media for
24 h and the amount of copper accumulated in the cells was determined.
The percentage copper retention represents the amount of copper retained in
the cells after a further 8 h incubation in media lacking 64Cu, expressed as a
percentage of the amount of 64Cu accumulated in cells during the 24-h
period. The samples are: Me32a, untransfected Menkes patient fibroblasts;
GM847, untransfected normal fibroblasts; Me32a–pNORM, Me32a trans-
fected with pNORM; Me32a–pALT, Me32a transfected with pALT;
GM847–pNORM, GM847 transfected with pNORM; GM847–pALT,
GM847 transfected with pALT. Values represent the meanF S.D. of three
independent measurements.
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was significantly reduced in comparison to the non-trans-
fected GM847 cells. After a further 8-h incubation in
medium without 64Cu, the amount of radioactive copper
retained within the cells was determined, to give an indirect
measure of copper efflux. The results demonstrated that
Menkes or normal cells transfected with either form of
sheep ATP7B retained significantly less copper than the
parental cell lines (Table 1), suggesting that sheep ATP7B
corrected the copper transport defect in these cells by
enhancing copper efflux, rather than by decreasing copper
uptake.
4. Discussion
The results of previous studies of the structure and
expression of sATP7B suggested that the gene could encode
a functional protein [16]. Similarly, in vitro analysis of
sATP7B demonstrated interaction with the copper chaper-
one SAH [24] and copper-induced trafficking in Chinese
hamster ovary (CHO) cells [17], properties required for
correct functioning of ATP7B. However, copper homeo-
stasis mediated by ATP7B is proposed to involve copper
transport across cellular membranes in addition to ligand-
induced trafficking of the molecule when copper is in excess
[8]. In this study, we demonstrated that the two forms of
sATP7B are functional copper-transporting molecules.
A diagnostic feature of Menkes disease is that cultured
cells derived from an affected individual hyper-accumulate
copper [25,26]. The functional complementation of the
copper accumulation phenotype of Menkes patient fibro-
blasts by ATP7A and ATP7B has demonstrated that these
cells constitute a valuable model for analysis of the copper
transport function of CPx-type ATPases [18,23]. RNA and
protein analysis confirmed the successful transfection and
expression of cDNA-derived sATP7B in Menkes and con-
trol fibroblasts. A significant level of sATP7B mRNA and
protein was detected in transfected fibroblasts, but not in
untransfected cells (Figs. 1 and 2).
Immunofluorescence analysis was used to assess the
intracellular distribution of sATP7B in the Menkes and
control fibroblasts and demonstrated that the two proteins
were similarly localised within the cell. In basal medium,
each form of sATP7B was localised to the perinuclear
region in transfected Menkes patient cells (Fig. 3). This
localisation was observed in cells expressing different levels
of the recombinant protein and was consistent with previous
studies which indicated that ATP7B is located at the TGN in
basal copper conditions [17,22]. The addition of 200 AM
copper to the medium did not appear to significantly alter
the localisation of sATP7B in the transfected cells (data not
shown). A similar apparent lack of response to copper was
observed when the cDNA-derived murine Atp7b protein
was expressed in the Me32a and GM847 cell lines [18],
suggesting that normal trafficking of ATP7B does not take
place in these fibroblast cells. In contrast, a significant
proportion of human ATP7B expressed in mottled mice
fibroblasts and HepG2 cells underwent a copper-induced
relocalisation to a vesicular, cytoplasmic compartment
[22,23]. It is difficult to reconcile these conflicting results,
but they do suggest that the cell type utilised for in vitro
studies may significantly influence the extent to which
copper-induced relocalisation of ATP7B is detectable.
Copper transport studies demonstrated that both forms of
sATP7B corrected the copper accumulation of Menkes
patient fibroblasts. Following a 24-h incubation in medium
containing trace amounts of 64Cu, the parental Me32a cell
line accumulated approximately three-fold more copper than
the control GM847 cell line (Table 1). The copper accumu-
lation in Me32a cells transfected with either form of sATP7B
was reduced in comparison to the non-transfected Me32a
cells and was comparable to the copper accumulation of the
control GM847 cell line. The reduced copper accumulation
of the Me32a cells transfected with pALT, in comparison to
pNORM, might have been due to higher expression levels of
alternate sATP7B, as suggested by the intensity of the
protected fragment in the RPA analysis (Fig. 1). Alterna-
tively, the difference may be the result of a larger proportion
of the G418-resistant population expressing pALT in com-
parison to pNORM. Similarly, the copper accumulation of
normal fibroblasts (GM847) transfected with either form of
sATP7B was significantly reduced in comparison to the non-
transfected GM847 cells. These observations were analo-
gous to those reported for functional murine and human
ATP7B expressed in Menkes and mottled fibroblasts [18,23].
After a further 8 h incubation in medium without 64Cu, the
amount of radioactive copper retained within the cells was
determined, to give an indirect measure of copper efflux. The
transfected Me32a and GM847 cells expressing sATP7B
retained similar proportions of copper as the non-transfected
control cell line, and this was substantially less than the non-
transfected Me32a cell line (Table 1). This result suggests
that sATP7B corrected the copper transport defect in these
cells by enhancing copper efflux, rather than by decreasing
copper uptake. These results demonstrate that both forms of
sATP7B are functional copper-transport proteins that can
reduce the intracellular copper content of fibroblasts by
enhancing copper efflux. Taken together with our previous
studies examining the structure, expression and localisation
of sATP7B [16,17,24], these results suggest that the copper
toxicosis syndrome of sheep may not result from defects in
the copper transport or localisation of either form of sheep
ATP7B. It is important to note that these studies utilised a
non-polarised cell culture system and the sheep ATP7B
proteins may have properties distinct from other mammalian
copper ATPases that are only apparent in hepatic cells which
have an apical (canalicular) and basolateral surface. Further-
more, the specific identity of the compartment to which
ATP7B traffics in response to elevated copper is yet to be
determined. If this is found to be different for the two forms
of sATP7B, it may suggest distinct roles for these proteins in
copper homeostasis. Future studies will be directed toward
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comparison of the sheep proteins in a polarised hepatic cell
line.
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